Five Below Inc (FIVE) Stock Price Today
Aura AI Summary
Key Stats
- $9.99BMARKET_CAP
- -VOLUME
- Consumer StaplesSECTOR
- $247.71FIFTY_TWO_WEEK_HIGH
- $128.79FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $10.88BENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Five Below Inc (FIVE) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Five Below Inc has traded between a low of $128.79 and a high of $247.71, highlighting its annual price range. Buy and sell Five Below Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Most Recent News
Juneteenth Exchange in Rancho Cordova unites leaders for innovation, investment, and AI-driven economic growth.
The inaugural Juneteenth Exchange summit in Rancho Cordova gathered over 150 leaders from business, technology, and investment sectors to discuss innovation, economic opportunity, and inclusive leadership. The event highlighted the city's growing app...

Tech sector drops 4.8% in first week of July, worst performer among S&P 500 sectors.
In the first week of July, the Technology sector fell 4.8%, making it the worst-performing sector among the S&P 500. Industrials, Consumer Discretionary, and Materials also declined but to lesser extents. Notably, 22 stocks that more than doubled in ...

Ionis Pharma's Phase-3 trial fails primary endpoint; shares drop 20% amid legal probe.
Ionis Pharmaceuticals announced that its Phase-3 CARDIO-TTRansform trial did not meet its primary endpoint, causing the company's shares to fall over 20%. The trial aimed to reduce cardiovascular death and recurrent events in patients with transthyre...
